The metabolic cost of lowering blood pressure with hydrochlorothiazide

Diabetology and Metabolic Syndrome

Volumn 5, Issue 1, 2013, Pages

  Price, Angela L ^a   Lingvay, Ildiko ^a   Szczepaniak, Edward W ^b   Wiebel, Jaime ^a   Victor, Ronald G ^b   Szczepaniak, Lidia S ^b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

Author keywords

Hydrochlorothiazide; Insulin secretion; Insulin sensitivity; Proton magnetic resonance spectroscopy; Type 2 diabetes; Valsartan

Indexed keywords

HYDROCHLOROTHIAZIDE; TRIACYLGLYCEROL; VALSARTAN;

ADULT; ANTIHYPERTENSIVE THERAPY; ARTICLE; CLINICAL ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; FAT MASS; FATTY LIVER; FEMALE; HEART FUNCTION; HEART MUSCLE; HUMAN; HYPERTENSION; INSULIN RELEASE; INSULIN SENSITIVITY; INTRAABDOMINAL FAT; LIPID LIVER LEVEL; LONGITUDINAL STUDY; MALE; OUTCOME ASSESSMENT; PANCREAS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SKELETAL MUSCLE; SUBCUTANEOUS FAT; TREATMENT OUTCOME;

EID: 84880008759     PISSN: None     EISSN: 17585996     Source Type: Journal    
DOI: 10.1186/1758-5996-5-35     Document Type: Article

References (26)

1. Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Barzilay JI, Davis BR, Cutler JA, Pressel SL, Whelton PK, Basile J, Margolis KL, Ong ST, Sadler LS, Summerson J, Arch Intern Med 2006 166 2191 2201 10.1001/archinte.166.20.2191 17101936 (Pubitemid 44748765)
2. Effect of antihypertensive agents on the development of type 2 diabetes mellitus. Stump CS, Hamilton MT, Sowers JR, Mayo Clin Proc 2006 81 796 806 10.4065/81.6.796 16770980 (Pubitemid 43841735)
3. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Elliott WJ, Meyer PM, Lancet 2007 369 201 207 10.1016/S0140-6736(07)60108-1 17240286 (Pubitemid 46111014)
4. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Gerstein HC, Yusuf S, Bosch J, Pogue J, Sheridan P, Dinccag N, Hanefeld M, Hoogwerf B, Laakso M, Mohan V, Shaw J, Zinman B, Holman RR, Lancet 2006 368 1096 1105 16997664
5. Antihypertensive therapy, new-onset diabetes, and cardiovascular disease. Basile JN, Int J Clin Pract 2009 63 656 666 10.1111/j.1742-1241.2009.02009.x 19220522
6. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide and Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. Califf RM, Boolell M, Haffner SM, Bethel MA, McMurray J, Duggal A, Holman RR, Am Heart J 2008 156 623 632 10.1016/j.ahj.2008.05.017 18946890
7. Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects. Karnes JH, Cooper-DeHoff RM, Expert Rev Cardiovasc Ther 2009 7 689 702 10.1586/erc.09.31 19505284
8. Antidiabetic mechanisms of angiotensin-converting enzyme inhibitors and angiotensin II receptor antagonists: beyond the renin-angiotensin system. Kurtz TW, Pravenec M, J Hypertens 2004 22 2253 2261 10.1097/00004872-200412000-00003 15614015 (Pubitemid 39625096)
9. Angiotensin Blockade Prevents Type 2 Diabetes by Formation of Fat Cells. Sharma AM, Janke J, Gorzelniak K, Engeli S, Luft FC, Hypertension 2002 40 609 611 10.1161/01.HYP.0000036448.44066.53 12411451 (Pubitemid 35278594)
10. Impaired fasting glucose and impaired glucose tolerance: implications for care. Nathan DM, Davidson MB, DeFronzo RA, Heine RJ, Henry RR, Pratley R, Zinman B, Diabetes Care 2007 30 753 759 10.2337/dc07-9920 17327355 (Pubitemid 46354366)
11. Lilly Lecture 1989. Toward Physiological Understanding of Glucose Tolerance. Minimal-Model Approach. Bergman RN, Diabetes 1989 38 1512 1527 10.2337/diabetes.38.12.1512 2684710 (Pubitemid 20006675)
12. In vivo determination of intra-myocellular lipids in human muscle by means of localized 1H-MR-spectroscopy. Boesch C, Slotboom J, Hoppeler H, Kreis R, Magn Reson Med 1997 37 484 493 10.1002/mrm.1910370403 9094069 (Pubitemid 27146825)
13. Comparison of localized proton NMR signals of skeletal muscle and fat tissue in vivo: two lipid compartments in muscle tissue. Schick F, Eismann B, Jung WI, Bongers H, Bunse M, Lutz O, Magn Reson Med 1993 29 158 167 10.1002/mrm.1910290203 8429779 (Pubitemid 23078508)
14. Measurement of intracellular triglyceride stores by H spectroscopy: validation in vivo. Szczepaniak LS, Babcock EE, Schick F, Dobbins RL, Garg A, Burns DK, McGarry JD, Stein DT, Am J Physiol 1999 276 977 E989 10329993
15. Bulk magnetic susceptibility effects on the assessment of intra- and extramyocellular lipids in vivo. Szczepaniak LS, Dobbins RL, Stein DT, McGarry JD, Magn Reson Med 2002 47 607 610 10.1002/mrm.10086 11870849 (Pubitemid 34194017)
16. Myocardial triglycerides and systolic function in humans: in vivo evaluation by localized proton spectroscopy and cardiac imaging. Szczepaniak LS, Dobbins RL, Metzger GJ, Sartoni-D'Ambrosia G, Arbique D, Vongpatanasin W, Unger R, Victor RG, Magn Reson Med 2003 49 417 423 10.1002/mrm.10372 12594743 (Pubitemid 36262808)
17. Magnetic resonance spectroscopy to measure hepatic triglyceride content: prevalence of hepatic steatosis in the general population. Szczepaniak LS, Nurenberg P, Leonard D, Browning JD, Reingold JS, Grundy S, Hobbs HH, Dobbins RL, Am J Physiol Endocrinol Metab 2005 288 462 E468 10.1152/ajpendo.00064.2004 15339742 (Pubitemid 40110657)
18. Adiposity of the heart, revisited. McGavock JM, Victor RG, Unger RH, Szczepaniak LS, Ann Intern Med 2006 144 517 524 10.7326/0003-4819-144-7- 200604040-00011 16585666 (Pubitemid 46780675)
19. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. McGavock JM, Lingvay I, Zib I, Tillery T, Salas N, Unger R, Levine BD, Raskin P, Victor RG, Szczepaniak LS, Circulation 2007 116 1170 1175 10.1161/CIRCULATIONAHA.106.645614 17698735 (Pubitemid 47360218)
20. Determination of triglyceride in the human myocardium by magnetic resonance spectroscopy: reproducibility and sensitivity of the method. Reingold JS, McGavock JM, Kaka S, Tillery T, Victor RG, Szczepaniak LS, Am J Physiol Endocrinol Metab 2005 289 935 E939 10.1152/ajpendo.00095.2005 15972271 (Pubitemid 41504396)
21. The fatty hearts of patients with diabetes. Lingvay I, Raskin P, Szczepaniak LS, Nat Rev Cardiol 2009 6 268 269 10.1038/nrcardio.2009.30 19352328
22. Noninvasive quantification of pancreatic fat in humans. Lingvay I, Esser V, Legendre JL, Price AL, Wertz KM, Adams-Huet B, Zhang S, Unger RH, Szczepaniak LS, J Clin Endocrinol Metab 2009 94 4070 4076 10.1210/jc.2009-0584 19773401
23. Relationships of generalized and regional adiposity to insulin sensitivity in men. Abate N, Garg A, Peshock RM, Stray-Gundersen J, Grundy SM, J Clin Invest 1995 96 88 98 10.1172/JCI118083 7615840
24. Hydrochlorothiazide, but not candesartan, aggravates insulin resistance and causes visceral and hepatic fat accumulation: the Mechanisms for the Diabetes Preventing Effect of Candesartan (MEDICA) Study. Eriksson JW, Jansson PA, Carlberg B, Hagg A, Kurland L, Svensson MK, Ahlstrom H, Strom C, Lonn L, Ojbrandt K, Johansson L, Lind L, Hypertension 2008 52 1030 1037 10.1161/HYPERTENSIONAHA.108.119404 18981327
25. Does it matter how blood pressure is lowered in patients with metabolic risk factors? Sharma AM, J Am Soc Hypertens 2008 4 23 S29
26. Differences in glucose tolerance between fixed-dose antihypertensive drug combinations in people with metabolic syndrome. Bakris G, Molitch M, Hewkin A, Kipnes M, Sarafidis P, Fakouhi K, Bacher P, Sowers J, Diab Care 2006 29 2592 2597 10.2337/dc06-1373 (Pubitemid 44912184)